03.30.15
Cordiva Medical has launched a multi-center research study to determine whether its new technology is effective at safely handing hazardous drugs. The study is being funded by the National Cancer Institute (NCI) as part of a series of Small Business Innovation Research (SBIR) grants,.
More than 5.5 million healthcare workers are at risk of exposure annually to hazardous drugs during the preparation and delivery of chemotherapy. Studies have shown that exposure to these hazardous pharmaceuticals can cause serious health problems, “such as cancers, reproductive and developmental problems…and other adverse events that can be irreversible even after low-level exposures,” according to the Occupational Safety & Health Administration, National Institute of Occupational Safety & Health (NIOSH), and Joint Commission.
The research partners involved in this study represent key opinion leaders in the field of oncology pharmacy and nursing. The Corvida NCI-funded SBIR study will evaluate improvements the company’s Closed System Transfer Device (CSTD) technology could bring to the safe handling of hazardous drugs. NIOSH has defined a CSTD as a drug transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system.
The NCI has awarded a series of grants totaling nearly $5 million to Corvida Medical. Grant funding provides sites with payment for participation as well as opportunities to collaborate in publication of findings.
“The grants from the NCI will help us advance Corvida’s soon-to-be-launched family of Halo brand CSTD products. The NCI SBIR study is a significant effort by the company to get leading cancer institutions in the U.S. to explore applications of Halo and to demonstrate forward movement in safe handling,” Cordiva Medical President/CEO Kent Smith said.
Headquartered in Coralville, Iowa, Corvida Medical develops technologies to safely handle hazardous drugs.
innovates intelligent technologies that represent the next generation of excellence in safe handling of hazardous drugs. The company’s first product, a new Closed System Transfer Device called the Halo, soon will be available (though it is not currently cleared for sale in the United States).
More than 5.5 million healthcare workers are at risk of exposure annually to hazardous drugs during the preparation and delivery of chemotherapy. Studies have shown that exposure to these hazardous pharmaceuticals can cause serious health problems, “such as cancers, reproductive and developmental problems…and other adverse events that can be irreversible even after low-level exposures,” according to the Occupational Safety & Health Administration, National Institute of Occupational Safety & Health (NIOSH), and Joint Commission.
The research partners involved in this study represent key opinion leaders in the field of oncology pharmacy and nursing. The Corvida NCI-funded SBIR study will evaluate improvements the company’s Closed System Transfer Device (CSTD) technology could bring to the safe handling of hazardous drugs. NIOSH has defined a CSTD as a drug transfer device that mechanically prohibits the transfer of environmental contaminants into the system and the escape of hazardous drug or vapor concentrations outside the system.
The NCI has awarded a series of grants totaling nearly $5 million to Corvida Medical. Grant funding provides sites with payment for participation as well as opportunities to collaborate in publication of findings.
“The grants from the NCI will help us advance Corvida’s soon-to-be-launched family of Halo brand CSTD products. The NCI SBIR study is a significant effort by the company to get leading cancer institutions in the U.S. to explore applications of Halo and to demonstrate forward movement in safe handling,” Cordiva Medical President/CEO Kent Smith said.
Headquartered in Coralville, Iowa, Corvida Medical develops technologies to safely handle hazardous drugs.
innovates intelligent technologies that represent the next generation of excellence in safe handling of hazardous drugs. The company’s first product, a new Closed System Transfer Device called the Halo, soon will be available (though it is not currently cleared for sale in the United States).